The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Exploiting drug-disease relationships for computational drug repositioning
Open accessAbstract
Finding new uses for existing drugs, or drug repositioning, has been used as a strategy for decades to get drugs to more patients. As the ability to measure molecules in high-throughput ways has improved over the past decade, it is logical that such data might be useful for enabling drug repositioning through computational methods. Many computational predictions for new indications have been borne out in cellular model systems, though extensive animal model and clinical trial-based validation are still pending. In this review, we show that computational methods for drug repositioning can be classified in two axes: drug based, where discovery initiates from the chemical perspective, or disease based, where discovery initiates from the clinical perspective of disease or its pathology. Newer algorithms for computational drug repositioning will likely span these two axes, will take advantage of newer types of molecular measurements, and will certainly play a role in reducing the global burden of disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Clustering by Passing Messages Between Data Points
Frey, B. J., & Dueck, D. (2007) · Science · doi:10.1126/science.1136800 · Cited by 6,758
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
The unified medical language system (UMLS): integrating biomedical terminology
Bodenreider, O. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh061 · Cited by 4,356
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248
Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide
Soignet, S. L., Maslak, P., Wang, Z.-G., Jhanwar, S., Calleja, E., Dardashti, L. J., Corso, D., DeBlasio, A., Gabrilove, J., Scheinberg, D. A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391901 · Cited by 1,213
An Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Adams, C. P., & Brantner, V. V. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.420 · Cited by 907
Fourches, D., Muratov, E., & Tropsha, A. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100176x · Cited by 832
Discovery of drug mode of action and drug repositioning from transcriptional responses
Iorio, F., Bosotti, R., Scacheri, E., Belcastro, V., Mithbaokar, P., Ferriero, R., Murino, L., Tagliaferri, R., Brunetti-Pierri, N., Isacchi, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000138107 · Cited by 816
In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
Ekins, S., Mestres, J., & Testa, B. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707305 · Cited by 703
A module map showing conditional activity of expression modules in cancer
Segal, E., Friedman, N., Koller, D., & Regev, A. (2004) · Nature Genetics · doi:10.1038/ng1434 · Cited by 685
Wei, G., Twomey, D., Lamb, J., Schlis, K., Agarwal, J., Stam, R. W., Opferman, J. T., Sallan, S. E., den Boer, M. L., Pieters, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.006 · Cited by 509
Lum, P. Y., Armour, C. D., Stepaniants, S. B., Cavet, G., Wolf, M. K., Butler, J. S., Hinshaw, J. C., Garnier, P., Prestwich, G. D., Leonardson, A., et al. (2004) · Cell · doi:10.1016/s0092-8674(03)01035-3 · Cited by 481
Molecular similarity analysis in virtual screening: foundations, limitations and novel approaches
Eckert, H., & Bajorath, J. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.01.011 · Cited by 466
Suthram, S., Dudley, J. T., Chiang, A. P., Chen, R., Hastie, T. J., & Butte, A. J. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000662 · Cited by 322
Self-citationKinnings, S. L., Liu, N., Buchmeier, N., Tonge, P. J., Xie, L., & Bourne, P. E. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000423 · Cited by 319
Human Disease-Drug Network Based on Genomic Expression Profiles
Hu, G., & Agarwal, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006536 · Cited by 310
Flexible ligand docking using conformational ensembles
Lorber, D. M., & Shoichet, B. K. (1998) · Protein Science · doi:10.1002/pro.5560070411 · Cited by 295
Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks
Yang, X., Deignan, J. L., Qi, H., Zhu, J., Qian, S., Zhong, J., Torosyan, G., Majid, S., Falkard, B., Kleinhanz, R. R., et al. (2009) · Nature Genetics · doi:10.1038/ng.325 · Cited by 288
Booth, B., & Zemmel, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1384 · Cited by 278
Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses
Chiang, A. P., & Butte, A. J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.103 · Cited by 268
Self-citationNew drug development in the United States from 1963 to 1999
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115132 · Cited by 251
Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Pijl, H., Ohashi, S., Matsuda, M., Miyazaki, Y., Mahankali, A., Kumar, V, Pipek, R., Iozzo, P., Lancaster, J. L., Cincotta, A. H., et al. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1154 · Cited by 238
PROMISCUOUS: a database for network-based drug-repositioning
von Eichborn, J., Murgueitio, M. S., Dunkel, M., Koerner, S., Bourne, P. E., & Preissner, R. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1037 · Cited by 225
Chang, R. L., Xie, L., Xie, L., Bourne, P. E., & Palsson, B. Ø. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000938 · Cited by 204
A Pathway-Based View of Human Diseases and Disease Relationships
Li, Y., & Agarwal, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004346 · Cited by 193
PubChem as a Source of Polypharmacology
Chen, B., Wild, D. J., & Guha, R. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci9001876 · Cited by 142
Can literature analysis identify innovation drivers in drug discovery?
Agarwal, P., & Searls, D. B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2973 · Cited by 100
Aronson, J. K. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03058.x · Cited by 91
Inverse In Silico Screening for Identification of Kinase Inhibitor Targets
Zahler, S., Tietze, S., Totzke, F., Kubbutat, M. H. G., Meijer, L., Vollmar, A. M., & Apostolakis, J. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.10.010 · Cited by 86
Qu, X. A., Gudivada, R. C., Jegga, A. G., Neumann, E., & Aronow, B. J. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-s5-s4 · Cited by 67
Drug Discovery in a Multidimensional World: Systems, Patterns, and Networks
Dudley, J. T., Schadt, E. E., Sirota, M., Butte, A. J., & Ashley, E. A. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9214-6 · Cited by 61
Self-citationNoeske, T., Sasse, B. C., Stark, H., Parsons, C. G., Weil, T., & Schneider, G. (2006) · ChemMedChem · doi:10.1002/cmdc.200600147 · Cited by 53
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
A survey of current trends in computational drug repositioning
Li, J., Zheng, S., Chen, B., Butte, A. J., Swamidass, S. J., & Lu, Z. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv020 · Cited by 555
Self-citationBuilding a knowledge graph to enable precision medicine
Chandak, P., Huang, K., & Zitnik, M. (2023) · Scientific Data · doi:10.1038/s41597-023-01960-3 · Cited by 522
Machine learning approaches and databases for prediction of drug–target interaction: a survey paper
Bagherian, M., Sabeti, E., Wang, K., Sartor, M. A., Nikolovska-Coleska, Z., & Najarian, K. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz157 · Cited by 429
Metadata
- Authors
- Dudley, J. T., Deshpande, T., & Butte, A. J.
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-20
- Volume
- 12
- Issue
- 4
- Pages
- 303-311
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- OpenAlex
- W2155157373
- Cited by
- 524
- References
- 37
- FWCI
- 24.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.